伊立替康联合顺铂与拓扑替康联合顺铂二线治疗小细胞肺癌的比较研究  

Comparative study of combined chemotherapy between irinotecan plus cisplation regimen and topotecan plus cisplation regimen in relapsed advanced small cell lung cancer

作　　者：柳影[1] 程颖[1] 张彩霞[1] 左学荣[1] 

机构地区：[1]吉林省肿瘤医院内一科,长春130012

出　　处：《临床肿瘤学杂志》2008年第11期984-987,共4页Chinese Clinical Oncology

摘　　要：目的:回顾性观察伊立替康联合顺铂(IP组)与拓扑替康联合顺铂(TP组)二线治疗难治型小细胞肺癌的近期、远期疗效及毒副作用。方法:共62例患者,均为一线EP方案治疗失败且在3～6个月内出现进展,IP组:伊立替康60mg/m2,第1、8天,DDP25mg/m2,第1～3天,静脉滴注;TP组:拓扑替康0.75mg/m2,第1～5天,DDP25mg/m2,第1～3天,静脉滴注。均21天为1周期。每2个周期评价疗效。结果:IP组30例,有效率33.3%(10/30),TP组32例,有效率37.5%(12/32),两组近期疗效无差异(P>0.05)。两组中位疾病进展时间(mTTP)均为3.0个月;中位生存期(MST)分别为12个月和11.5个月,无显著性差异(P>0.05)。两组毒副作用主要表现为:Ⅲ～Ⅳ度粒细胞下降TP组高于IP组(31.3%vs.23.3%),但两组无显著性差异(P>0.05);Ⅲ～Ⅳ度血小板下降TP组高于IP组(18.8%vs.6.6%),两组有显著性差异(P<0.05);延迟性腹泻IP组高于TP组(30.0%vs.3.1%)。结论:伊立替康联合顺铂与拓扑替康联合顺铂二线治疗难治型小细胞肺癌均取得较好疗效,两方案毒副作用均可以耐受。Objective：To compare the efficacy and toxicity between IP（irinoteean plus cisplation）and TP（ topotecan plus cisplatin） regimen in the second-line treatment of recurrent small cell lung cancer. Methods：Sixty-two cases of recurrent small cell lung cancer were enrolled. Thirty cases were treated with IP regiment （ ifinoteean 60mg/m^2, d1 , d8 , cisplation 25mg/m^2 iv gtt d1 -d3 ） ,32 eases were treated with TP regiment （topotecan 0. 75mg/m^2 iv gtt d1 -d5 ,cisplation 25mg/m^2 iv gtt d1-d3 ）. Results：For the cases with IP regimen,the overall response rate was 33.3% （10/30）. For the cases with TP regimen,the overall response rate was 37.5% （12/32）. There was no significant difference between two groups（ P 〉 0.05 ）. Major toxicity was myelosuppression. Ⅲ-Ⅳ grade leucocytopenia for TP regimen was higher than IP regimen（ 31.25% versus 23.3% ,P 〉 0.05 ） , Ⅲ-Ⅳ grade thromboeytopenia for TP regimen was higher than IP regimen （ 18.8% versus 6. 6% , P 〈 0. 05 ） , tardive diarrhea for IP regimen was higher than TP regimen （30. 0% versus 3.1% , P 〈 0. 01 ）. Conclusion：TP and IP regimen in the second-line treatment of recurrent small cell lung cancer has good chinieal efficancy and tolerability.

关 键 词：伊立替康 拓扑替康 小细胞肺癌 联合化疗 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]